Tandem Diabetes Care, Inc. (NASDAQ:TNDM – Get Free Report) shares rose 7.9% during trading on Tuesday after Stifel Nicolaus raised their price target on the stock from $37.00 to $40.00. Stifel Nicolaus currently has a buy rating on the stock. Tandem Diabetes Care traded as high as $34.36 and last traded at $34.24. Approximately 229,124 shares traded hands during mid-day trading, a decline of 87% from the average daily volume of 1,715,144 shares. The stock had previously closed at $31.73.
Several other equities research analysts have also recently commented on the stock. Citigroup boosted their price objective on shares of Tandem Diabetes Care from $31.00 to $38.00 and gave the company a “neutral” rating in a research report on Wednesday, April 3rd. StockNews.com raised shares of Tandem Diabetes Care from a “sell” rating to a “hold” rating in a research report on Friday, April 19th. One research analyst has rated the stock with a sell rating, six have given a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $37.27.
View Our Latest Report on Tandem Diabetes Care
Institutional Investors Weigh In On Tandem Diabetes Care
Tandem Diabetes Care Trading Up 0.4 %
The firm’s 50 day moving average price is $30.51 and its two-hundred day moving average price is $25.18. The company has a debt-to-equity ratio of 0.91, a quick ratio of 3.02 and a current ratio of 3.83.
Tandem Diabetes Care (NASDAQ:TNDM – Get Free Report) last released its quarterly earnings data on Wednesday, February 21st. The medical device company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.04). Tandem Diabetes Care had a negative return on equity of 31.48% and a negative net margin of 29.77%. The firm had revenue of $196.80 million for the quarter, compared to analyst estimates of $204.86 million. Research analysts expect that Tandem Diabetes Care, Inc. will post -1.62 EPS for the current fiscal year.
Tandem Diabetes Care Company Profile
Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.
See Also
- Five stocks we like better than Tandem Diabetes Care
- What is the FTSE 100 index?
- High-Yield Texas Instruments Could Hit New Highs Soon
- Best Stocks Under $5.00
- Pagaya Technologies: An AI Fintech That Insiders Are Buying
- What Are Dividend Contenders? Investing in Dividend Contenders
- Higher Oil Prices Could Give NextEra’s Stock Earnings a Boost
Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.